论文部分内容阅读
[目的]探讨康复新液灌肠联合美沙拉嗪治疗溃疡性结肠炎(UC)的疗效。[方法]132例轻中度UC患者,随机分成2组,治疗组66例,给予康复新液100 ml,1次/d,灌肠;美沙拉嗪1 g,3次/d,口服。对照组66例,给予美沙拉嗪1 g,3次/d,口服。2组均予益生菌辅助治疗。于治疗8周后观察2组症状的缓解情况,同时复查电子结肠镜观察治疗效果。[结果]8周后临床症状:治疗组完全缓解率63.64%,总有效率为95.45%;对照组完全缓解率48.48%,总有效率为83.33%;2组比较差异有统计学意义(P<0.05)。电子结肠镜:治疗组完全缓解率63.64%,总有效率为96.97%;对照组完全缓解率46.97%,总有效率为81.82%;2组比较差异有统计学意义(P<0.05)。[结论]康复新液灌肠联合美沙拉嗪治疗UC临床疗效较好。
[Objective] To investigate the curative effect of Kangfu Xinye enema and mesalazine on ulcerative colitis (UC). [Method] 132 patients with mild-to-moderate UC were randomly divided into two groups. The treatment group was given 66 mg of Kangfuxin Solution once a day, enema and mesalazine 1 g thrice daily. The control group of 66 patients were given mesalazine 1 g, 3 times / d, orally. 2 groups were given adjuvant probiotics. After 8 weeks of treatment, the symptoms of the two groups were observed and the results were observed electron microscopy. [Results] After 8 weeks clinical symptoms: The complete remission rate was 63.64% in the treatment group, the total effective rate was 95.45%; the complete remission rate in the control group was 48.48%, the total effective rate was 83.33%; the difference between the two groups was statistically significant (P < 0.05). In the treatment group, the complete remission rate was 63.64% and the total effective rate was 96.97%. The complete remission rate was 46.97% in the control group and the total effective rate was 81.82%. The difference between the two groups was statistically significant (P <0.05). [Conclusion] Kang Fu Xin liquid enema combined mesalazine treatment of UC clinical efficacy is better.